Clinical Applications of Circulating Tumor Cells in Pharmacotherapy: Challenges and Perspectives

Wu, Tong; Cheng, Bin; Fu, Liwu

doi:10.1124/mol.116.108142

Cited by 16 publications

(15 citation statements)

References 108 publications

(74 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 4 , 7 In fact, due to the low concentration of CTCs, ctDNA, and EXOs currently recoverable from the patient, the analytical results sometimes suffer from unsatisfactory specificity and sensitivity. 25 , 177 – 179 The use of different high-throughput analytical platforms often results in difficulty in reproducing results, and highlights the need for standardization and analytical validation of the method used for liquid biopsy. 180 , 181 In the same way, computational analysis needs new tools that can elaborate complex algorithms of data interpretation and clinical correlation of molecular data.…”

Section: Conclusion and Future Perspectivesmentioning

confidence: 99%

Liquid biopsy of cancer: a multimodal diagnostic tool in clinical oncology

et al. 2018

View full text Add to dashboard Cite

Over the last decades, the concept of precision medicine has dramatically renewed the field of medical oncology; the introduction of patient-tailored therapies has significantly improved all measurable outcomes. Liquid biopsy is a revolutionary technique that is opening previously unexpected perspectives. It consists of the detection and isolation of circulating tumor cells, circulating tumor DNA and exosomes, as a source of genomic and proteomic information in patients with cancer. Many technical hurdles have been resolved thanks to newly developed techniques and next-generation sequencing analyses, allowing a broad application of liquid biopsy in a wide range of settings. Initially correlated to prognosis, liquid biopsy data are now being studied for cancer diagnosis, hopefully including screenings, and most importantly for the prediction of response or resistance to given treatments. In particular, the identification of specific mutations in target genes can aid in therapeutic decisions, both in the appropriateness of treatment and in the advanced identification of secondary resistance, aiming to early diagnose disease progression. Still application is far from reality but ongoing research is leading the way to a new era in oncology. This review summarizes the main techniques and applications of liquid biopsy in cancer.

show abstract

Section: Conclusion and Future Perspectivesmentioning

confidence: 99%

Liquid biopsy of cancer: a multimodal diagnostic tool in clinical oncology

et al. 2018

View full text Add to dashboard Cite

show abstract

“…The efficiency of ddPCR allows to extend its applicability to other very important field of biomedicine, such as liquid biopsies in tumor patients (where the presence of tumor-free circulating DNA content is similar to fetal circulating DNA) (Wu et al, 2017 ).…”

Section: Discussionmentioning

confidence: 99%

Non-invasive fetal sex diagnosis in plasma of early weeks pregnants using droplet digital PCR

D’Aversa

Breveglieri

Pellegatti

et al. 2018

Mol Med

View full text Add to dashboard Cite

BackgroundFetal sex determination is useful for families at risk of X-linked disorders, such as Duchenne muscular dystrophy, adrenal hypoplasia, hemophilia. At first, this could be obtained through invasive procedures such as amniocentesis and chorionic villus sampling, having a 1% risk of miscarriage. Since the discovery of cell-free fetal DNA (cffDNA) in maternal plasma, noninvasive prenatal testing permits the early diagnosis of fetal sex through analysis of cffDNA. However, the low amount of cffDNA relative to circulating maternal DNA requires highly sensitive molecular techniques in order to perform noninvasive prenatal diagnosis. In this context we employed droplet digital PCR (ddPCR) in order to evaluate the earliest possible fetal sex determination from circulating DNA extracted from plasma of pregnant women at different gestational ages.MethodsWe identified the fetal sex on cffDNA extracted from 29 maternal plasma samples at early gestational ages, several of them not suitable for qPCR determination, using ddPCR designed for SRY gene target.ResultsAll maternal plasma samples were determined correctly for SRY gene target using ddPCR even at very early gestational age (prior to 7 weeks).ConclusionsThe ddPCR is a robust, efficient and reliable technology for the earliest possible fetal sex determination from maternal plasma.

show abstract

“…[107] Analysis of CTCs can help to identify patients a high risk, to differentiate benign from malign disease and guide therapy; however, the limitations and intricacies of the interpretations of the cancer cells detected has to be considered comprehensively. [108] …”

Section: Discussionmentioning

confidence: 99%

Circulating Tumor Cells in the Parallel Invasion Model Supporting Early Metastasis

Hamilton¹,

Rath²

2018

Oncomedicine

View full text Add to dashboard Cite

Circulating tumor cells (CTCs) seem to comprise metastasis-initiating cells and their count and phenotype represent an indicator of prognosis and response to therapy in cancer patients. In the classical model of tumor dissemination, specialized cells at the invasive front undergo epithelial-mesenchymal transition (EMT) and enter peripheral tumor-coalescing blood vessels to establish metastatic lesions by extravasation of CTCs. Thus, dissemination of cancer cells occurs after prolonged tumor development and following access to neighboring blood vessels via transit through stromal tissue. However, clinical and new experimental data indicate early tumor dissemination immediately after an angiogenic switch has occurred and an intravasation of tumor cells in the tumor core region. Accordingly, CTCs may have direct access through fenestrated and irregular intratumoral vessels and, therefore, the metastasis-initiating cells become active a long time before lesions are detected clinically. This model of cancer cell intravasation is better compatible with the release of CTC clusters and apoptotic CTCs and, furthermore, spares the requirement for an elusive and complicated EMT/MET program. Similarly, the intravasation of large number of CTCs observed in metastatic disease may be alleviated by an intratumoral process instead of a stromal crossing. This early metastasis model changes the possible pathways targeted for the prevention and inhibition of metastasis and the significance of CTCs which are detected and analyzed late after the initial phase of tumor dissemination.

show abstract

Clinical Applications of Circulating Tumor Cells in Pharmacotherapy: Challenges and Perspectives

Cited by 16 publications

References 108 publications

Liquid biopsy of cancer: a multimodal diagnostic tool in clinical oncology

Liquid biopsy of cancer: a multimodal diagnostic tool in clinical oncology

Non-invasive fetal sex diagnosis in plasma of early weeks pregnants using droplet digital PCR

Circulating Tumor Cells in the Parallel Invasion Model Supporting Early Metastasis

Contact Info

Product

Resources

About